<DOC>
	<DOCNO>NCT00478309</DOCNO>
	<brief_summary>RATIONALE : The Genetic Epidemiology Risk Assessment program may effective usual care increase number healthy participant regularly receive screen colorectal cancer . PURPOSE : This randomized clinical trial study Genetic Epidemiology Risk Assessment program see well work compare usual care increase colorectal cancer screen healthy participant .</brief_summary>
	<brief_title>Genetic Epidemiology Risk Assessment Program Usual Care Colorectal Cancer Screening Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : - Compare Genetic Epidemiology Risk Assessment ( GERA ) feedback v usual care ( UC ) term colorectal cancer ( CRC ) screen utilization healthy participant . - Determine impact GERA feedback UC psychological distress participant . - Compare GERA feedback v UC term intention CRC screening , perceive CRC risk , CRC knowledge , salience coherence CRC screening , support CRC screening participant . - Identify factor moderate impact GERA feedback CRC screen utilization . OUTLINE : This randomize study . Participants randomize 1 2 screening arm . - Arm I : Participants receive standard primary care . - Arm II : Participants receive standard primary care follow Genetic Epidemiology Risk Assessment ( GERA ) intervention . Participants also participate discussion session regard GERA include rationale behind methylenetetrahydrofolate reductase mutation detection folate assessment relationship colorectal cancer risk . All participant undergo fecal occult blood test 3 week screen office visit . PROJECTED ACCRUAL : A total 1,950 participant accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Healthy participant meet follow criterion : No personal history colorectal polyp cancer inflammatory bowel disease No family history familial adenomatous polyposis , hereditary nonpolyposis colorectal cancer ( CRC ) , CRC 1 firstdegree relative Nonadherent standard CRC screen recommendation time index office visit PATIENT CHARACTERISTICS : Able communicate ease English PRIOR CONCURRENT THERAPY : More 6 week since prior antibiotic antifolate medication ( e.g. , sulfasalazine , methotrexate )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>healthy , evidence disease</keyword>
</DOC>